Study of MRG003 plus HX008 for EGFR-positive penile cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests two drugs, MRG003 and HX008, as a first treatment for men with EGFR-positive penile squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if the combination shrinks tumors or delays growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have penile squamous cell carcinoma that is locally advanced or has spread to other parts of the body and cannot be removed with surgery.
- Your tumor must test positive for EGFR (a protein on cancer cells).
- You must not have received any previous cancer treatment for advanced disease.
- You must be a man 18 years or older.
- You must be in good overall health (able to do daily activities) with adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
This trial tests two drugs — becotatug vedotin and pucotenlimab — together in people with advanced penile cancer whose tumors show a protein called EGFR. It aims to see if this combination can shrink or slow the cancer.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
This trial tests a new targeted therapy (DEC003M) for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to see if this treatment is safe and helps shrink tumors.
This trial tests MRG003, a cancer medicine, in people with recurrent or metastatic squamous cell carcinoma of the head and neck who have already tried and had trouble with standard treatments like platinum and anti–PD-1 therapy. It looks at whether the treatment can shrink the cancer and how safe it is.
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
Hear when a new Penile Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.